The RNA-based therapeutics involves broad range of the RNA-based technologies, which help the patients to diagnose or treat various chronic diseases. The RNA-based therapeutics play a crucial role in providing the accurate and precise healthcare treatments, which helps in treating the disease at molecular and sub-molecular levels. RNA-based therapeutic modalities provide beneficial business opportunities due to its rising acceptance, technological advancements and targeted drug delivery of these therapeutics as compared to the other treatment modalities (synthetic therapeutics). The Asia-Pacific RNA-based therapeutics market is growing at a promising CAGR due to the gene silencing potential of these therapeutics. However, the market is still at the nascent stage in developing regions such as India and witnessing the lucrative growth rate during the analysis period. Factors that would fuel the market growth in Asia-Pacific region are target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, high cost coupled with the high failure rates and reimbursement issues related with the adoption of RNA-based therapeutics would restrain the market growth.
The Asia-Pacific RNA-based therapeutics market is segmented on the basis of technology, application, end user and geography. Based on technology, the market is segmented into enabling technologies, enabled technologies and RNA antisense technologies. Owing to the applications, the market is segmented into cardiovascular diseases, kidney diseases, oncology infectious diseases and metabolic disorders. Based on the end users, the market is categorized into diagnostic, therapeutic and research organizations. Geographically, the market is segmented into China, Japan, India, Australia and others. Emerging economies such as India, China, Singapore and Malaysia are the potential geographies for market expansion due to improving healthcare standards. These economies have a large presence of domestic manufacturers of RNA-based therapeutics, which contribute to an increase in the market competition for multinational giants by adopting the strategy of price penetration.
Companies profiled in this report are Genzyme Corporation, Tekmira Pharmaceuticals Corp, Biocon ltd, Nitto Denko Corporation, Alnylam Pharmaceuticals, Inc. Acorda Therapeutics Inc., Arrowhead Research Corporation, Abingworth Life Science, Silence Therapeutics PLC, AstraZeneca Inc., and Catalyst Biosciences.
KEY BENEFITS
This report includes extensive coverage of the Asia-Pacific RNA-based therapeutics market including drivers, restraints and opportunities that would help professionals to better understand market behavior
Analyzing the current market trends, projections regarding the market potential for the period of 20142021 in terms of value are discussed
A comprehensive analysis of device types, end users and geography segments enables the identification of growth opportunities within the Asia-Pacific RNA-based therapeutics market
Market attractiveness analysis for the market would provide strategic assistance to decision makers
An analysis of strategies used by key leaders within the Asia-Pacific RNA-based therapeutics market would prove to be informative for professionals in the corporate sector
Porters five forces framework examines the competitive structure of Asia-Pacific RNA-based therapeutics market and would be helpful for strategic industry analysis
Ease of doing business analysis would help in making strategic business decisions
ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET KEY SEGMENTS
The Asia-Pacific RNA-based therapeutics market is segmented on the basis of technology, application, end users and geography segments.
BY TECHNOLOGY
Enabling technologies
Microarrays
Labelling
Purification
Linear amplification
QRT-PCR
Inhibition
Enabled tec
The Asia-Pacific RNA-based therapeutics market is segmented on the basis of technology, application, end user and geography. Based on technology, the market is segmented into enabling technologies, enabled technologies and RNA antisense technologies. Owing to the applications, the market is segmented into cardiovascular diseases, kidney diseases, oncology infectious diseases and metabolic disorders. Based on the end users, the market is categorized into diagnostic, therapeutic and research organizations. Geographically, the market is segmented into China, Japan, India, Australia and others. Emerging economies such as India, China, Singapore and Malaysia are the potential geographies for market expansion due to improving healthcare standards. These economies have a large presence of domestic manufacturers of RNA-based therapeutics, which contribute to an increase in the market competition for multinational giants by adopting the strategy of price penetration.
Companies profiled in this report are Genzyme Corporation, Tekmira Pharmaceuticals Corp, Biocon ltd, Nitto Denko Corporation, Alnylam Pharmaceuticals, Inc. Acorda Therapeutics Inc., Arrowhead Research Corporation, Abingworth Life Science, Silence Therapeutics PLC, AstraZeneca Inc., and Catalyst Biosciences.
KEY BENEFITS
This report includes extensive coverage of the Asia-Pacific RNA-based therapeutics market including drivers, restraints and opportunities that would help professionals to better understand market behavior
Analyzing the current market trends, projections regarding the market potential for the period of 20142021 in terms of value are discussed
A comprehensive analysis of device types, end users and geography segments enables the identification of growth opportunities within the Asia-Pacific RNA-based therapeutics market
Market attractiveness analysis for the market would provide strategic assistance to decision makers
An analysis of strategies used by key leaders within the Asia-Pacific RNA-based therapeutics market would prove to be informative for professionals in the corporate sector
Porters five forces framework examines the competitive structure of Asia-Pacific RNA-based therapeutics market and would be helpful for strategic industry analysis
Ease of doing business analysis would help in making strategic business decisions
ASIA PACIFIC RNA-BASED THERAPEUTICS MARKET KEY SEGMENTS
The Asia-Pacific RNA-based therapeutics market is segmented on the basis of technology, application, end users and geography segments.
BY TECHNOLOGY
Enabling technologies
Microarrays
Labelling
Purification
Linear amplification
QRT-PCR
Inhibition
Enabled tec
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
